Previous close | 25.450 |
Open | 25.050 |
Bid | 24.900 x N/A |
Ask | 24.950 x N/A |
Day's range | 24.300 - 25.500 |
52-week range | 10.320 - 32.200 |
Volume | |
Avg. volume | 4,569,478 |
Market cap | 7.968B |
Beta (5Y monthly) | 2.16 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.920 |
Earnings date | 28 Mar 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 26.95 |
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company") announced that the Hong Kong Department of Health had approved Nefecon® for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression. Hong Kong marks the fourth region in Everest territories that Nefecon® received New Drug Application (NDA) approval after Singapore, Macau and mainland China. Nefecon® received full U.S. Food and Drug Administration (FDA) approval in December 2023.
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative medicines and vaccines, today announced its financial results for the full year ended December 31, 2023, along with a corporate update.
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative medicines and vaccines, announced today that the Singapore Health Sciences Authority (HSA) has approved NEFEGAN® for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression. NEFEGAN®, known in other Everest territories as Nefecon®, was the first ever treatment for IgAN full